| Sign In to gain access to subscriptions and/or personal tools. |
Clinical and Applied Thrombosis/Hemostasis, Vol. 14, No. 3, 286-294 (2008) DOI: 10.1177/1076029607304726 Ocular Vascular Thrombotic Events: Central Retinal Vein and Central Retinal Artery OcclusionsJewish Hospital Cholesterol Center, glueckch{at}healthall.com
Jewish Hospital Cholesterol Center,
University of Cincinnati Medical Center
Cincinnati Eye Institute Cincinnati, Ohio
University of Cincinnati Medical Center
We prospectively assessed associations of thrombophilia— hypofibrinolysis with central retinal vein occlusion (CRVO) (40 patients) and central retinal artery occlusion (CRAO) (9 patients). We used polymerase chain reaction measures for thrombophilia (factor V Leiden, prothrombin, C677T MTHFR, platelet glycoprotein PlA1/A2) and hypofibrinolysis (plasminogen activator inhibitor-1 4G4G). Serologic thrombophilia measures included protein C, protein S (total and free) and antithrombin III, homocysteine, lupus anticoagulant, anticardiolipin antibodies IgG-IgM, and factors VIII and XI. Serologic hypofibrinolysis measures included Lp(a) and plasminogen activator inhibitor activity. For comparison with 40 CRVO and 9 CRAO patients, 80 and 45 race—gender matched controls were studied. The factor V mutation was more common in CRVO (3/40, 8%) than controls (0/79, 0%), P = .036, as was high (>150%) factor VIII (12/40, 30%) versus (4/77, 5%), P = .0002. Low antithrombin III (<80%) was more common in CRVO (5/39, 13%) than in controls (2/73, 3%), P = .049. Homocysteine was high (
Key Words: thrombophilia hypofibrinolysis central retinal vein thrombosis central retinal artery thrombosis
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
13.5 µmol/L) in 5/39 (13%) CRVO patients versus 2/78 controls (3%), P = .04. Three of 9 CRAO patients (33%) had low (<73%) protein C versus 2/37 controls (5%), P = .044. Two of 9 CRAO patients (22%) had high (